Access Press Releases and Stay Up-to-Date on Venture Capital and Private Equity Trends
Summary
"Our pioneering effort to introduce a first-of-its-kind test to market is a testament to our unwavering commitment to offer advanced solutions to gastroenterologists in their pursuit of providing a proactive and personalized approach to the treatment of Barretts esophagus and the prevention of esophageal cancer. Esopredict delivers timely and accurate risk predictions over a 5-year horizon and identifies changes in the DNA methylation levels of four genes, using a sample of a patients Barretts esophagus cells to provide a result report called the Esoscore. In addition to launching Esopredict, Previse also raised a $3M seed round, with participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and numerous angel investors. Previse will use the seed funding to rapidly expand commercial operations and to build prospective clinical utility research that is the cornerstone for creating broad insurance coverage and reimbursement for Esopredict. Previses technology was made possible by grants from the National Institutes of Health ("NIH") and developed after decades of research by the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine.